Background on Generic Approval and Market Entry

Amneal Pharmaceuticals' (AMRX) macitentan 10mg oral tablets, a treatment for pulmonary arterial hypertension (PAH), received final approval from the U.S. Food and Drug Administration (FDA) on June 8, 2026, and has been launched in the U.S. market. This final approval marks a significant milestone in overcoming the patent barrier of Opsumit, the blockbuster originator drug developed by Johnson & Johnson's (JNJ) subsidiary, Actelion, which was first approved on October 18, 2013. Having passed bioequivalence testing, Amneal has also resolved patent litigation, eliminating legal risks, and can now provide a more affordable treatment option for patients in the U.S.

Opsumit's Sales Trend and Generic Competition

Opsumit, the originator drug, is the most widely prescribed endothelin receptor antagonist (ERA) in the PAH treatment market, blocking both endothelin A and B (ETA/ETB) receptors. Global annual sales of Opsumit (including Opsynvi combination therapy) have decreased from $2.184 billion (approximately 2.9 trillion KRW) in 2024 to $1.633 billion (approximately 2.2 trillion KRW) in 2025, and this generic launch is expected to further accelerate the erosion of the originator's market share. With Zydus, Apotex, and Alembic, among others, already having entered the market, competition for market share and pricing is expected to intensify.

PAH Treatment Market, Mechanism, and Safety Management

The global PAH treatment market is growing from approximately $7.9 billion to $8.3 billion in 2024 to $8.0 billion to $8.5 billion in 2025, and macitentan plays a key role in lowering pulmonary artery pressure by inhibiting endothelin receptors, which cause vasoconstriction. Despite its potent therapeutic efficacy, macitentan is contraindicated in pregnant women due to the risk of fetal harm and is distributed in the U.S. only under a Risk Evaluation and Mitigation Strategy (REMS) program. The cost savings from the availability of generics are expected to significantly improve medication adherence in PAH patients, who require long-term treatment.

Amneal's Business Diversification and Future Financial Prospects

Amneal Pharmaceuticals is focusing on diversifying its portfolio of complex generic products, and the successful launch of macitentan will undoubtedly be a solid pipeline that will drive the company's sales in the medium to long term. The erosion of market share due to the expiration of the originator patent is a financial blow to Johnson & Johnson, but it presents a golden opportunity for later generic companies like Amneal to tap into a multi-billion dollar niche market. Amneal plans to leverage its price competitiveness to negotiate listing in the formularies of major pharmacy benefit managers (PBMs) in the U.S., aiming for early market penetration and improved profitability.